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Abstract: Cyclic nucleotide phosphodiesterases (PDEs) hydrolyze the intracellular second 
messengers cAMP and cGMP to their corresponding monophosphates. PDEs play an important 
role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. 
We have previously shown that the individual haplotype GAACC in the PDE11A gene was 
associated with major depressive disorder (MDD) based on block-by-block analysis. There are 
two PDE genes, PDE11A and PDE1A, located in chromosome 2q31–q32. In this study, we 
have further explored whether the whole region 2q31–q32 contribute to MDD or antidepressant 
response 278 depressed Mexican-American participants and 321 matched healthy controls. 
Although there is no signiﬁ  cant interaction between the two genes, the remission rate of individual 
carrying the combination genotype at rs1880916 (AG/AA) and rs1549870 (GG) is signiﬁ  cantly 
increased. We analyzed the global haplotype by examining 16 single-nucleotide polymorphisms 
(SNPs) in PDE11A and six SNPs in PDE1A. None of the haplotypes consisting of six SNPs 
in the PDE1A have a signiﬁ  cant difference between depressed and control groups. Among 
haplotypes consisting of 16 SNPs across 440 kb in the PDE11A gene, 18 common haplotypes 
(with frequency higher than 0.8%) have been found in the studied population. Six haplotypes 
showed signiﬁ  cantly different frequencies between the MDD group and the control group. The 
phylogenetic network result for the 16 SNPs showed that several historic recombination events 
have happened in the PDE11A gene. The frequency of one haplotype is signiﬁ  cantly lower in 
the remitter group than in the nonremitter group for the depressed participants treated with 
either desipramine or ﬂ  uoxetine. Thus, our data suggest that the PDE11A global haplotype is 
associated with both MDD and antidepressant drug response.
Keywords: PDE11A, major depression, antidepressant, haplotype, linkage disequilibrium, 
recombination
Introduction
The 3', 5'-cyclic nucleotides cAMP and cGMP function as second messengers in a 
wide variety of signal transduction pathways. 3', 5'-cyclic nucleotide phosphodies-
terases (PDEs) catalyze the hydrolysis of cAMP and cGMP to the corresponding 
5’-monophosphates and provide a mechanism to downregulate cAMP- and cGMP-
signaling. Human PDEs are composed of 21 genes and are categorized into 11 families 
based on sequence homology, enzymatic properties, and sensitivity to inhibitors.1–3
PDE11A gene is the most recently identiﬁ  ed and cloned member of the PDE 
protein superfamily.4 Four N-terminal transcript variants (PDE11A1, A2, A3, and A4) 
encoding different isoforms have been found for this gene.5,6 The PDE11A1, A2, and 
A3 have a catalytic domain and an N-terminus GAF domain, while the full-length 
form, PDE11A4, contains two GAF domains and a catalytic domain.4–7 The GAF 
domain in PDE11A is homologous to other signaling molecule as found in PDE2, 
PDE5, PDE6, and PDE10.1–3,8 The GAF domain is involved in high afﬁ  nity allosteric 
cGMP and other small signaling molecules binding. Because of their unique ligand-
binding topologies, the GAF domains of PDEs are likely to offer good new targets Neuropsychiatric Disease and Treatment 2009:5 164
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for rational drug design.9 PDE11A exhibits properties of 
dual-substrate PDE and hydrolyzes both cAMP and cGMP 
into AMP and GMP respectively with similar Km values.4–6 
The Km for cAMP and cGMP were similar for all the four 
PDE11A variants.4–6
Haplotypes provide a record of evolution history more 
accurately than individual single-nucleotide polymorphisms 
(SNPs), they can also capture linkage disequilibrium (LD) 
and recombination hotspots information of a genomic region 
more completely. Individual haplotype results detected by 
haplotype blocks may vary considerably from different 
algorithms since the methods for block deﬁ  nition are still 
under devising and no single approach is appropriate for 
all datasets.10 If a recombination hotspot occurs within one 
gene, using this gene as candidate may not be appropriate. 
An alternative to individual haplotype association study is 
to perform multimarker association analysis with multiple 
adjacent markers,11 that is global haplotype. In unrelated indi-
viduals, PHASE program has been widely used to infer the 
most likely haplotype that an individual has inherited.11 Since 
we previously demonstrated a signiﬁ  cant association between 
an individual haplotype in the PDE11A gene and major 
depressive disorder (MDD),12 and two PDE genes (PDE11A 
and PDE1A) are located in chromosome 2q31–q32, we now 
evaluate if the whole region 2q31–q32 is associated with 
MDD by analyzing the gene–gene interaction. Combinations 
of the individual haplotypes in multiple loci might determine 
the complexity of an individual’s susceptibility for MDD and 
outcome of antidepressant treatment. Therefore, we aimed to 
do the haplotype phasing before block partition using PHASE 
software by examining 16 SNPs across the PDE11A and six 
SNPs on the PDE1A gene in this study.
Materials and methods
Participants
This study was approved by the IRBs of the University of 
California Los Angeles and the University of Miami, and it 
has been registered in ClinicalTrials.gov (NCT00265292). 
Genomic DNA samples from 599 Mexican-Americans were 
used in this study: 278 depressed participants enrolled in a 
pharmacogenetic study of antidepressant treatment response 
to desipramine or ﬂ  uoxetine, and 321 age- and sex-matched 
control participants recruited from the same Mexican-American 
community in Los Angeles.12,13 Controls were in general 
good health but were not screened for medical or psychiatric 
illness. Inclusion criteria included DSM-IV diagnosis of a 
current unipolar major depressive episode, with a 21-item 
Hamilton Depression Rating Scale (HAM-D21) score14 
of  18 with item number 1 (depressed mood) rated  2. 
Detailed inclusion and exclusion criteria for both control 
and depressed participants were described previously.12,13,15 
We used diagnostic and ratings instruments that have been 
fully validated in English and Spanish, and all assessments 
were conducted in the participants’ primary language. All 
Mexican-American participants aged 21–68 years had at 
least three grandparents born in Mexico. Written informed 
consent was obtained from each participant.
All patients had an initial comprehensive psychiatric 
and medical assessment and, if enrolled, had nine weeks of 
structured follow up assessments. The study consisted of 
two phases: a 1-week single-blind placebo lead-in phase to 
minimize the impact of placebo responders followed, if par-
ticipants continue to meet the inclusion criteria after phase 1, 
by random assignment to one of the two treatment groups: 
ﬂ  uoxetine 10–40 mg/day or desipramine 50–200 mg/day, 
administered in a double-blind manner for eight weeks, 
with blind dose escalation based on clinical outcomes. In the 
depressed group, 230 participants received treatment in our 
double-blind clinical trial. Of those, 143 patients completed 
the study, 61 attained remission, deﬁ  ned as having a ﬁ  nal 
HAM-D21 score of  8, and the remainder (n = 82) were 
categorized as nonremitters.
Genotype procedure
The Illumina human SNP linkage analysis platform (Illumina, 
San Diego, CA) was used for genotyping.16,17 Brieﬂ  y, all 
genomic DNAs were quantitated using PicoGreen and 
diluted into 100 ng/μl concentration. Then, the DNAs were 
transferred into seven bar-coded plastic 96-well conical 
microtiter plates. Genotyping of 27 SNPs on the PDE1A 
and PDE11A genes was done at the Wellcome Trust Sanger 
Institute (Hinxton, UK) using the Golden Gate assay 
(Illumina) and following the manufacturers’ instruction.16 
All genotypes were evaluated using a quantitative quality 
score called GenCall score. A GenCall score ranges from 
0 to 1 and reﬂ  ects the proximity within a cluster plot of the 
intensities of that genotype to the centroid of the nearest 
cluster. Poorly performing samples were removed from the 
genotyping report ﬁ  les, and individual genotypes with Gen-
Call scores below 0.25 were assigned a nocall. Data quality 
was assessed by duplicate DNAs (n = 26) across all plates. 
Genotypes from nonmatching duplicates were dropped; they 
were also dropped if they had one missing data point. Devia-
tion from Hardy–Weinberg equilibrium (HWE) was tested 
separately for the control and depressed groups by using the 
ALLELE procedure in SAS/Genetics 9.1.3 (SAS Institute, Neuropsychiatric Disease and Treatment 2009:5 165
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Cary, NC). SNPs that were not in HWE in the control group 
(p   0.05) and SNPs that were monoallelic in both groups 
were excluded. After the cleaning and ﬁ  ltering steps, 599 
DNA samples genotyped for 22 SNPs on the PDE11A and 
PDE1A genes (Table 1) were used for the global haplotype 
analysis. Given the number of comparisons by a Bonferonni 
or similar adjustment would be too conservative, thus we have 
stated the nominal p-value so that the reader can assess the 
magnitude of signiﬁ  cance. Chi-square test with Monte Carlo 
permutation test and Fisher’s exact test conducted to evaluate 
the association between the SNP and MDD as well as anti-
depressant drug response. We concluded that the allele was 
associated with MDD or antidepressant drug response when 
all the methods had the concordant association results.
A confounding factor that may impact the internal valid-
ity of case-control studies is the presence of population 
stratiﬁ  cation. We used two approaches to test for the hidden 
population stratiﬁ  cation in our data.18 Firstly, 54 unlinked 
SNPs across 22 autosomal chromosomes were employed to 
analyze a combined sample with the genotype data download 
from three HapMap ethnic samples using STRUCTURE 
program. Three distinct clusters were identiﬁ  ed with an 
average proportion of at least 92% of individuals correctly 
assigned to the given ethnic populations (CEU, CHB + 
JPT, YRI). We then used this panel of SNPs to test our 
sample and observed an almost equal proportion assigned 
to each clusters given K = 2, 3, 4 in both cases and controls. 
Secondly, genotype frequencies from each of the 54 unlinked 
SNPs were compared between cases and controls using the 
previous described method.18 In our study population, no 
signiﬁ  cant difference was found based on an overall test 
statistic (χ2 = 100.50, df = 108, p = 0.68). Therefore, our data 
show that there is no signiﬁ  cant evidence of stratiﬁ  cation in 
the study population.
Table 1 List of the 22 SNPs on chromosome 2q31–q32 that have been included for global haplotype analysis
Order SNPa Allele Chromosome 
position
Gene Region Distance 
between 
SNPs (BP)
Minor allele frequency P valueb
Depression Control
1 rs1997207 C/G 178331945 PDE11A Intron 19 0.06115 0.07886 0.2339
2 rs3770018 A/C 178366311 PDE11A Intron 16 34,367 0.05755 0.112 0.000863
3 rs1465831 G/T 178394581 PDE11A Intron 13 28,271 0.02698 0.04416 0.113
4 rs3770034 G/A 178426123 PDE11A Intron 10 31,543 0.1367 0.1577 0.3077
5 rs1866212 A/G 178428793 PDE11A Intron 10 2671 0.1787 0.1577 0.3342
6 rs1561320 T/C 178429529 PDE11A Intron 10 737 0.1241 0.1562 0.1131
7 rs1866209 G/A 178432866 PDE11A Intron 10 3,338 0.1241 0.1562 0.1131
8 rs1370656 A/C 178433505 PDE11A Intron 10 640 0.06835 0.09621 0.08242
9 rs998059 G/T 178437777 PDE11A Intron 10 4273 0.1241 0.1577 0.09731
10 rs1438048 C/A 178438353 PDE11A Intron 10 577 0.1241 0.1562 0.1131
11 rs3770045 C/G 178454734 PDE11A Intron 10 16,382 0.2428 0.2855 0.09622
12 rs1370661 G/A 178529090 PDE11A Intron 6 74,357 0.2104 0.235 0.3098
13 rs2037757 G/A 178561572 PDE11A Intron 5 32,483 0.3201 0.3785 0.03523
14 rs1405647 A/C 178584369 PDE11A Intron 4 22,798 0.2176 0.235 0.4748
15 rs1880916 G/A 178620937 PDE11A Intron 2 36,569 0.1151 0.142 0.1686
16 rs744397 T/C 178684625 PDE11A Intron 2 63,689 0.1619 0.1845 0.3033
17 rs1432531 A/G 182833008 PDE1A Intron 14 4,148,384 0.2518 0.2508 0.968
18 rs1991765 A/G 182864440 PDE1A Intron 14 31,433 0.2284 0.224 0.855
19 rs1432534 G/T 182882952 PDE1A Intron 11 18,513 0.2176 0.2271 0.6942
20 rs3769788 A/G 182884887 PDE1A Intron 11 1936 0.2302 0.2256 0.8482
21 rs1432518 A/G 182923743 PDE1A Intron 5 38,857 0.3489 0.3281 0.4481
22 rs1549870 A/G 182943110 PDE1A Intron 3 19,368 0.05576 0.05047 0.6847
Notes: aThree SNPs, rs1866209, rs998059, and rs1438048, were ﬁ  rst reported here. Other SNPs have been analyzed in previous published paper;12 bThe p values correspond 
to the comparison of allele frequencies between the depression and control groups.
Abbreviations: BP, base pair; SNP, single-nucleotide polymorphisms; PDE, phosphodiesterase.Neuropsychiatric Disease and Treatment 2009:5 166
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Haplotype analysis with PHASE software 
and statistic analysis
Maximum likelihood estimates of haplotype frequencies 
were calculated in control, depressed, remitter, and non-
remitter groups using the program PHASE (v2.1.1).19,20 
The haplotypes were estimated with PHASE in the whole 
group of participants, and then compared their distribution 
between groups. The phase reconstruction method regards 
the unknown haplotypes as unobserved random quantities 
and aims to evaluate their conditional distribution in light 
of the genotype data via using Markov chain–Monte Carlo 
algorithm. We analyzed the haplotype diversity including 
16 SNPs on the PDE11A gene and six SNPs on the PDE1A 
gene. The haplotypes obtained by PHASE have been 
conﬁ  rmed by other two haplotype estimation approaches, ie, 
PLINK v-1.01 and Haploview v-4.0. As shown in Tables 1 
and 3, for identiﬁ  cation and naming purposes, the order of 
SNPs for haplotyping started with the intron 19 of PDE11A 
and continued 3' to 5' up the PDE11A and PDE1A genes. 
Fisher’s exact test was conducted to evaluate the association 
between the haplotype/genotype, and MDD as well as anti-
depressant drug response. Fisher’s exact test is a procedure 
that one can use for data in a two by two contingency table 
and allows one or two of the cell values less than ﬁ  ve.
Additive gene–gene interaction was analyzed to test 
the combined effect from both PDE11A and PDE1A for 
antidepressant response. Brieﬂ  y, Rothman’s synergy index 
(S)21 measure proposed by Rothman was used to assess the 
joint effect of the two SNPs, rs1880916 on the PDE11A 
gene and rs1549870 on the PDE1A gene. The S index is the 
ratio of the observed joint effect divided by the expected 
joint effect assuming additivity of the effects, deﬁ  ned as: 
S = (OR11−1)/(OR10 + OR01−2) in which subscript 0 denotes 
the absence of the risk genotype at the SNP and OR denotes 
the odds ratio. No interaction corresponds to S = 1, whereas 
S   1 (S   1) can be interpreted as a measure of relative 
increase (decrease) in the effect among those exposed to risk 
genotypes at both SNPs.
Phylogenetic network analysis 
in the PDE11A gene
To analyze the phylogenetic relationship of haplotypes 
consisting of 16 SNPs in the PDE11A gene among 278 
depressed Mexican-Americans and 321 controls, a reduced-
median-network was constructed using Network 4.2.0.1 
program (http://www.ﬂ  uxus-engineering.com/).22
Results
SNPs associated with MDD 
and antidepressant response
For the 22 SNPs crossing region 2q31–q32 (Table 1), three 
SNPs, including rs1866209, rs998059, and rs1438048, are 
ﬁ  rst reported here to examine the PDE11A gene further 
density. Two SNPs on the PDE11A gene, rs3770018 and 
rs2037757, are associated with MDD; another two SNPs, 
rs1880916 on the PDE11A gene and rs1549870 on the 
PDE1A gene, are associated with attaining remitter and 
nonremitter status within the entire depressed group treated 
with either desipramine and ﬂ  uoxetine, which is concordance 
with our previous ﬁ  ndings.12 The remission rate of individuals 
carrying the minor allele A at rs1880916 in PDE11A or the 
homozygous for the major allele G at rs1549870 in PDE1A 
is about 50% (Table 2). Moreover, the remission rate is 
81% in the combined genotype at rs1880916 (AG/AA) and 
rs1549870 (GG). The dramatically increased remission rate 
suggested that the combination genotype of these two SNPs 
could predict the antidepressant response, although there is 
no signiﬁ  cant interaction between the two genes (S ≈ 1; 
Table 2).
Haplotype diversity in the PDE11A gene 
in depression and control groups
There is no significant frequency difference between 
the MDD and control groups when running haplotype 
analysis for six SNPs in the PDE1A gene. When includ-
ing 16 SNPs across 440kb in the PDE11A gene, a total of 
Table 2 Combined effect of PDE11A and PDE1A genes on the antidepressant response
No. of risk allele rs1880916 rs1549870 Remitter/nonremitter Remission rate % RR (95% CI) p value
0 GG AG/AA 2/11 0.15 1.00 –
1 GG GG 55/42 0.57 3.69 (1.02–13.34) 0.047
2 AG/AA AG/AA 3/3 0.50 3.25 (0.72–14.64) 0.125
3 AG/AA GG 22/5 0.81 5.30 (1.46–19.19) 0.011
Note: Rothman synergy index = (5.30–1)/(3.25 + 3.69 − 2) ≈1.
Abbreviations: CI, conﬁ  dence interval; RR, relative risk.Neuropsychiatric Disease and Treatment 2009:5 167
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70 different haplotypes were identiﬁ  ed. The haplotype H1 
(3'-CAGAGCACGCCAAAGC-5'), with the highest frequency 
in the population, has frequencies of 61.3%, 58.3%, 63.8%, and 
59.8% in the MDD, control, remitter, and nonremitter groups, 
respectively (Table 3). Eighteen common haplotypes (with 
frequency higher than 0.8%) account for frequencies of 87.2%, 
89.4%, 85.4%, and 89.3% in MDD, control, remitter, and non-
remitter groups, respectively (Table 3). The frequency of two 
haplotypes (H4: 3'-CAGAACACGCCAAAGC-5' and H12: 
3'-CAGGATGATACAGAAT-5') is signiﬁ  cantly higher in 
the MDD group than in the control group (p   0.05). The 
haplotype H4 consists of the individual haplotype GAACC, 
which has been previously reported to be associated with 
MDD.12 Four other haplotypes (H3, H15, H16, and H18) 
have lower frequency in the MDD group than that in control 
group (p   0.05). We also calculated the ﬁ  rst ten highest 
frequency genotypes in the MDD group and compared 
between the MDD and control groups. The frequencies of 
genotypes H1/H4 and H2/H4 are signiﬁ  cant higher in MDD 
than that of control group (Table 4). Therefore, combined 
with the genotype distribution between the MDD and control 
groups, the frequencies of the haplotypes H2, H4, and H12 
are higher in the depressed group, and the frequencies of the 
haplotypes H7, H11, H14, H15, H16, and H18 are lower in 
this same group (Tables 3 and 4). The frequency of the hap-
lotype H8: 3'-CAGAGCACGCGGGCGC-5' is signiﬁ  cantly 
lower in the remitter than that of nonremitter group for the 
depressed participants treated with either desipramine or 
ﬂ  uoxetine (Table 3).
The results from both linkage disequilibrium analysis 
and phylogenetic network for the 16 SNPs showed that eight 
historic recombinations have happened in the PDE11A gene, 
including SNP1, 2, 5, 11, 12, 14, 15, and 16, showed in the 
boxes in Figure 1.
Discussion
The ultimate goal of our ongoing research is to ﬁ  nd genetic 
variations that are associated with susceptibility to depres-
sion/antidepressant drug response and to use this information 
to identify genetic markers. Several lines of investigation 
support that hyperactivity of the hypothalamic-pituitary-
adrenal (HPA) axis resulting from hyperactive hypothalamic 
Table 3 Estimated frequency for 16-locus (SNP1–16)a haplotype in depression (MDD), control groups (CT), remitter (R), and nonremitter 
groups (NR)
Order Sequenceb Diagnosis Antidepressant treatment Note
MDD (%)
N = 556
CT (%)
N = 642
p value R (%) 
N = 164
NR (%)
N = 122
p value
H1 CAGAGCACGCCAAAGC 341 (61.3) 374 (58.3) 0.288 104 (63.4) 73 (59.8) 0.541 Common
H2 CAGGATGCTAGGGCGC 27 (4.7) 26 (4.1) 0.574 7 (4.3) 6 (4.9) 0.783 MDD
H3 CAGAGCACGCGAGAAT 26 (4.7) 49 (7.6) 0.042 10 (6.1) 6 (4.9) 0.797 Common
H4 CAGAACACGCCAAAGC 18 (3.2) 0 (0)  0.001 6 (3.7) 4 (3.3) 1.000 MDD
H5 CAGAGCACGCCGGCGC 14 (2.5) 19 (3.0) 0.598 4 (2.4) 5 (4.1) 0.503 Common
H6 CAGGATGATACGGCGC 9 (1.6) 8 (1.3) 0.631 3 (1.8) 1 (0.8) 0.639 Common
H7 GAGAGCACGCCAAAGC 8 (1.4) 15 (2.3) 0.205 0 (0) 3 (2.5) 0.077 Normal
H8 CAGAGCACGCGGGCGC 8 (1.4) 12 (1.9) 0.654 0 (0) 5 (4.1) 0.013 Common
H9 GAGAGCACGCGAGAAT 8 (1.4) 10 (1.6) 1.000 2 (1.2) 0 (0) 0.509 Common
H10 CAGAGCACGCGGGCGT 6 (1.1) 4 (0.6) 0.528 1 (0.6) 3 (2.5) 0.316 Common
H11 CCGGATGATACGGCGC 6 (1.1) 17 (2.7) 0.057 0 (0) 2 (1.6) 0.181 Normal
H12 CAGGATGATACAGAAT 5 (0.9) 0 (0) 0.021 1 (0.6) 0 (0) 1.000 MDD
H13 CAGGATGATAGGGCGC 5 (0.9) 5 (0.8) 0.759 1 (0.6) 0 (0) 1.000 Common
H14 CCGAGCACGCGAGAAT 4 (0.7) 9 (1.4) 0.280 1 (0.6) 0 (0) 1.000 Normal
H15 CAGAGCACGCCAGAAT 0 (0) 6 (0.9) 0.033 0 (0) 0 (0) 1.000 Normal
H16 CCGAGCACGCGGGCGC 0 (0) 8 (1.3) 0.009 0 (0) 0 (0) 1.000 Normal
H17 CCGGATGCTAGGGCGT 0 (0) 5 (0.8) 0.065 0 (0) 0 (0) 1.000 Common
H18 GAGAGCACGCCGGCGC 0 (0) 7 (1.1) 0.017 0 (0) 0 (0) 1.000 Normal
Total   485 (87.2) 574 (89.4)     140 (85.4) 109 (89.3)
Notes: aSee Table 1 for deﬁ  nitions of the SNP1–16, and the haplotype is from 3' to 5' in PDE11A; bThe SNPs are bold and underlined in the haplotype that is different with most 
common haplotype.
Abbreviations: MDD, major depressive disorder; SNP, single-nucleotide polymorphisms; PDE, phosphodiesterase.Neuropsychiatric Disease and Treatment 2009:5 168
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corticotropin-releasing hormone (CRH) neurons and elevated 
cortisol levels are associated with major depression.23,24 It 
is well known that Cushing syndrome25 may be caused by 
increased levels of cortisol resulting from adrenocorticotropic 
hormone (ACTH)-producing pituitary tumors that are resistant 
to glucocorticoid negative feedback. Increased cAMP signal-
ing has been linked to genetic forms of cortisol excess and 
leads to adrenocortical tumors and Cushing syndrome26 and 
cAMP levels are regulated by PDEs. Recently, a genetic form 
of Cushing has been linked to PDE dysfunction. Genome-wide 
SNP genotyping study of adrenocortical tumor tissues showed 
that they had 2q31–2q35 loss of heterozygosity (LOH), 
decreased protein expression and high cyclic nucleotide 
levels and cAMP-responsive element-binding protein (CREB) 
phosphorylation.27 Mutations in the PDE11A gene are a cause 
of Cushing disease and adrenocortical hyperplasia.27,28 In this 
study, we tested the association of the region 2q31–q32, which 
includes the PDE11A and PDE1A genes, and MDD. We found 
the remission rate of individual who had the minor allele A at 
rs1880916 in PDE11A and homozygous for the major allele G 
at rs1549870 in PDE1A is dramatically increased. This result 
is potentially useful for depression treatment as a clinical guide 
in the future. However, we did not ﬁ  nd association between 
PDE1A and MDD or antidepressant response by studying 
six-SNP haplotype on the PDE1A gene.
PDE11A contains a single GAF domain at the N terminus 
similar to but distinct from the tandem GAF domains found 
in PDE2, PDE5, PDE6, and PDE10.1–3,8 GAF acronym comes 
from the names of the ﬁ  rst three classes of proteins recognized 
to contain this domain: mammalian cGMP-binding PDEs, 
Anabaena adenylyl cyclases, and Escherichia coli FhlA.29 
There are now 2,334 GAF domains in 1,996 proteins in the 
nonredundant SMART domain database (as of 10/08/2007), 
of which only 15 (0.66%) GAF domains in 8 (0.41%) proteins 
pertain to humans and nearly all of the GAF domains identi-
ﬁ  ed are in PDEs.30,31 GAF domains in PDEs provide multiple 
functional roles and therefore PDEs genes may associate 
with the diagnosis and treatment outcome of MDD through 
modulating intracellular levels of cGMP. The GAF domain 
makes PDEs particularly attractive therapeutic targets for 
manipulation of cAMP and cGMP signaling. The PDE11A 
and PDE1A genes have been included in the study because 
(1) they are located within 2q31–35, (2) as we indicated 
previously, the PDE11A individual haplotype is associated 
with MDD and three SNPs on PDE11A and PDE1A are 
associated with antidepressant drug response,12 and (3) the 
PDE11A gene has the GAF domain. PDE11A functions as a 
dual-substrate PDE that regulate both cGMP and cAMP under 
physiological conditions,4–6 and is a large gene with 440 kb. 
Eight recombination spots have been found in the 16 SNPs 
crossing the PDE11A gene. The linkage disequilibrium map 
of the PDE11A gene in the studied Mexican-Americans is 
similar to the haplotype blocks deﬁ  ned in other studies.32 Our 
data showed that the global haplotype on the PDE11A gene 
is associated with MDD as well as antidepressant response, 
which is in concordance with our previous results from indi-
vidual SNPs and individual haplotype analysis.12 Our result is 
different from another study, which did not ﬁ  nd association 
between the variants in PDE11A and citalopram response.33 
The difference may result from different population studied or 
different antidepressant medication used in two studies. We 
have found that the genotypes H1/H4 and H2/H4 have signiﬁ  -
cantly higher frequency in the MDD group than in the control 
group. Furthermore, the haplotype H4 has a high frequency 
in the MDD with 3.2% and is absent in the control group, 
which rises the probability of the haplotype contribution to 
MDD. However, the present haplotypes could only be esti-
mated statistically and the frequencies under 5% may result 
in inconsistent associations. Therefore, the real haplotypes of 
the PDE11A gene must be determined experimentally. This 
would provide an understanding of the mechanisms under-
lying the genetic variation in MDD and antidepressant drug 
response among the population and would enable the predic-
tion of the risk of MDD. It might be possible to perform the 
required experiments using a recently reported new method 
Table 4 Estimated frequency for 16-locus (SNP1–16)a genotype in 
depression (MDD), control groups (CT), remitter (R), and nonremitter 
groups (NR)
Genotype Diagnosis Antidepressant 
response
MDD (%)
(N = 278)
CT (%) 
(N = 321)
R (%) 
(N = 82)
NR (%) 
(N = 61)
H1/H1b 115 (41.4) 120 (37.4) 34 (41.5) 26 (42.6)
H1/H2 14 (5.0) 14 (4.4) 5 (6.1) 3 (4.9)
H1/H3 18 (6.5) 26 (8.1) 8 (9.8) 4 (6.6)
H1/H4 8 (2.9) 0 (0)** 3 (3.7) 1 (1.6)
H1/H5 10 (3.6) 13 (4.0) 3 (3.7) 4 (6.6)
H1/H6 8 (2.9) 5 (1.6) 2 (2.4) 1 (1.6)
H1/H8 4 (1.4) 7 (2.2) 0 (0) 2 (3.3)
H1/H9 5 (1.8) 6 (1.9) 2 (2.4) 0 (0)
H2/H3 4 (1.4) 4 (1.2) 1 (1.2) 2 (3.3)
H2/H4 4 (1.4) 0 (0)* 1 (1.2) 1 (1.6)
Notes: MDD vs CT: *p = 0.046; **p = 0.002; aSee Table 1 for deﬁ  nitions of the SNP1–16, 
and the haplotype is from 3' to 5' in PDE11A; bThe haplotype is named after Table 3.
Abbreviations: MDD, major depressive disorder; SNP, single-nucleotide polymor-
phisms; PDE, phosphodiesterase.Neuropsychiatric Disease and Treatment 2009:5 169
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for long-range haplotype determination.34 Also, some of the 
SNPs on the PDE11A gene should be tested if they affect 
enzymatic function in vitro with variable changes in cAMP 
and/or cGMP levels in lymphocyte blood cells.
In conclusion, we identiﬁ  ed three PDE11A global haplo-
types that are associated with MDD and one with antidepres-
sant drug response. These ﬁ  ndings suggest that drugs targeted 
to affect PDE function, particularly GAF-related PDEs, could 
represent a new treatment strategy for major depression. 
A more focused study of functions related to the haplotypes 
in the PDE11A gene will improve our understanding of how 
genetic factors might contribute to individual susceptibility 
for major depression and antidepressant drug response.
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